The efficacy and safety of biweekly valganciclovir 450 mg for prophylaxis of recurrent cytomegalovirus anterior uveitis

Abstract

Abstract Viral anterior uveitis (AU) can be caused by a multitude of viruses, including cytomegalovirus (CMV). It can be a potentially vision-threatening condition. Thus, it requires prompt diagnosis and treatment as well as long-term prophylaxis to prevent the dire effects of recurrences. This case involved a 45-year-old Egyptian woman with a long history of unilateral recurrent AU that was polymerase chain reaction proven to be due to CMV. She was treated with oral valganciclovir and then placed on maintenance therapy. In this case, we shed the light on the possibility of reducing the prophylactic dose to a 450 mg biweekly dose of oral valganciclovir. Considering a lower dose of oral valganciclovir may help practitioners avoid the side effects of oral valganciclovir as well as reduce the overall financial burden in long-term prophylaxis.